Search Results 3531-3540 of 22476 for oral

  1. Non-Hodgkin's Lymphoma Clinical Trials - Mayo Clinic Research

    Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed ...

  4. Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) - Mayo Clinic

    ... (oral vs rectal vs both oral and rectal); (3) role of oral budesonide in patients mild-moderate UC; (4) comparative effectiveness and tolerability of rectal ...

  5. Faculty Misconduct Policy - Mayo Clinic College of Medicine and Science

    Allegation: Any written or oral statement or other indication of possible faculty misconduct made to education administration or leadership. Faculty ...

  6. A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) - Mayo Clinic

    About this study. The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of a single oral administration of CP101 for the ...

  7. Multiple endocrine neoplasia, type 2 (MEN 2) - Symptoms and causes - Mayo Clinic

    Types · MEN 2A . This also is known as classical MEN 2A or Sipple syndrome. It causes medullary thyroid cancer and noncancerous tumors of the parathyroid glands ...

  8. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    ... oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; or intrauterine hormone-releasing system).

  9. Ph.D. Training Program in Virology and Gene Therapy - Mayo Clinic

    Eligibility. Predoctoral appointees must be enrolled in Mayo Clinic Graduate School of Biomedical Sciences' Ph.D. Program, have completed the written and oral ...

  10. Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405) - Mayo Clinic

    Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is ...